Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 20:9:1014257.
doi: 10.3389/fmed.2022.1014257. eCollection 2022.

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Martina Catalano  1 , Giandomenico Roviello  2 , Ilaria Camilla Galli  3 , Raffaella Santi  2 , Gabriella Nesi  3
Affiliations
Review

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Martina Catalano et al. Front Med (Lausanne). .

Abstract

Although immune checkpoint inhibitors (ICIs) have dramatically revolutionized the field of oncology over the last decade, severe immune-related adverse events (irAEs) are potentially life-threatening. In comparison with toxicities involving the skin, gastrointestinal tract and endocrine system, nephrotoxicity is less common but often underestimated due to difficult diagnosis. Management usually consists of treatment discontinuation and/or corticosteroid use. In this review, we summarize current knowledge of ICI-induced nephrotoxicity, evaluating drawbacks and future perspectives.

Keywords: ICI-induced acute kidney injury; immune checkpoint inhibitors; immune-related adverse events; multidisciplinary management; nephrotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. (1996) 271:1734–6. 10.1126/science.271.5256.1734 - DOI - PubMed
    1. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. (2016) 375:1767–78. 10.1056/NEJMra1514296 - DOI - PMC - PubMed
    1. Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. . Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase i dose-escalation study. J Clin. Oncol. 36:391–398. 10.1200/JCO.2017.72.2850 - DOI - PMC - PubMed
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. . Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. (2018) 379:2342–50. 10.1056/NEJMoa1809697 - DOI - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. . Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. (2015) 372:2018–28. 10.1056/NEJMoa1501824 - DOI - PubMed

LinkOut - more resources